• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Aimee Tharaldson Discusses 2 New Treatments for Tardive Dyskinesia

Video

The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

The market for tardive dyskinesia, a movement disorder affecting 500,000 patients in the United States, will go from zero approved treatments to 2 in 2017, making it an important area to watch, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

Transcript

Is there a disease or a new drug category that payers aren't paying enough attention to?

I think tardive dyskinesia is one area that maybe a lot of payers aren't thinking about right now. Right now there are 2 drugs that are pending approval for tardive dyskinesia [Editor note: the first was approved on April 11, 2017].

So this is a condition where there's abnormal, repetitive movements. And right now there's nothing approved to treat these patients. It can be caused from high doses of dopamine, blocking agents, and chronic use of these medications. And there's about 500,000 patients in the United States that have tardive dyskinesia. Right now, Xenazine is sometimes used off label. It's a 3 times daily medication. It's only approved for Huntington's disease chorea, so that's an orphan condition. Xenazine can cause depression and suicidal ideation, so there's a lot of safety concerns with it.

But there are 2 drugs that are going to be approved for tardive dyskinesia this year, which affects 500,000 patients in the US. Ingrezza will be the first one, that's once daily, and that's expected to be approved April 11. And then Austedo, it's initially going to be approved for Huntington's disease chorea [Editor's note: it was approved April 5, 2017], that orphan condition. But it is pending approval for tardive dyskinesia, as well. So that expanded indication could occur sometime in August of this year.

So we'll have 2 new drugs for tardive dyskinesia, large patient population. It will be interesting to see how much these medications cost. Right now, for Huntington's disease, Xenazine is about $150,000 per year, but you know as the population broadens significantly with these 2 new medications it will be interesting to see how they're priced. So those are important ones to watch.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.